A Philadelphia cell therapy developer has initiated its first human testing of a potential cancer treatment. Vittoria ...

PHILADELPHIA, PA — Vittoria Biotherapeutics, Inc. has announced the launch of its Phase 1 clinical trial for VIPER-101, a ...

Trial is evaluating VIPER-101, a novel, gene edited, autologous dual-population CAR-T therapy in patients with T cell lymphomaVIPER-101 was ...

More than four years later—and after two rejections from the agency—Mesoblast has finally gained an endorsement from the U.S.

Regulatory Approval Showcases Clinical Advancement of Linea DNA™ as a Rapid and Effective Means of Producing CAR-T cell Therapies -STONY BROOK, ...

Antibody-drug conjugates (ADCs) represent a promising cancer treatment modality designed to deliver highly potent cytotoxic ...

Opna Bio AG has presented promising data regarding their EP300/CBP inhibitor OPN-6602 for the treatment of multiple myeloma (MM). The inhibition of EP300/CBP causes cell cycle arrest and apoptosis in ...

hindering tumor-T cell interactions,” the investigators wrote. The newly reported study proposed that inhibiting EZH2 might help enhance the potency and durability of immunotherapies.

A new study suggests fat cells keep a memory of previous weight gain, which may help to explain why this happens. Losing weight can be a lot of work, which makes it all the more frustrating when ...

they found that it indeed killed the cancer cells with high potency. They also tested the molecule in healthy mice and found no obvious toxic side effects, even though the molecule killed off a ...